RT Journal Article
SR Electronic
T1 Development of a Predictive Score for COVID-19 Diagnosis based on Demographics and Symptoms in Patients Attended at a Dedicated Screening Unit
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.14.20101931
DO 10.1101/2020.05.14.20101931
A1 Alexandre P. Zavascki
A1 Marcelo B. Gazzana
A1 João Pedro M. Bidardt
A1 Patrícia S. Fernandes
A1 Aline Galiotto
A1 Cristiane T. Kawski
A1 Luiz Antonio Nasi
A1 Diego R. Falci
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.05.14.20101931.abstract
AB Background The diagnosis of COVID-19 based on clinical evaluation is difficult because symptoms often overlap with other respiratory diseases. A clinical score predictive of COVID-19 based on readily assessed variables may be useful in settings with restricted or no access to molecular diagnostic tests.Methods A score based on demographics and symptoms was developed in a cross-sectional study including patients attended in a dedicated COVID-19 screening unit. A backward stepwise logistic regression model was constructed and values for each variable were assigned according to their β coefficient values in the final model. Receiver operating characteristic (ROC) curve was constructed and its area under the curve (AUC) was calculated.Results A total of 464 patients were included: 98 (21.1%) COVID-19 and 366 (78.9%) non-COVID-19 patients. The score included variables independently associated with COVID-19 in the final model: age ≥60 years (2 points), fever (2), dyspnea (1), fatigue (1 point) and coryza (-1). Score values were significantly higher in COVID-19 than non-COVID-19 patients: median (Interquartile Range), 3 (2–4), and 1 (0–2), respectively; P<0.001. The score had an AUC of 0.80 (95% Confidence Interval [CI], 0.76–0.86). The specificity of scores ≥4 and ≥5 points were 90.4 (95%CI, 87.0–93.3) and 96.2 (95%CI, 93.7–97.9), respectively.Conclusions This preliminary score based on patients’ symptoms is a feasible tool that may be useful in setting with restricted or no access to molecular tests in a pandemic period, owing to the high specificity. Further studies are required to validate the score in other populations.Competing Interest StatementA. P. Z. received research grant not related to this study from Pfizer. D.R.F. has received payment for research grants, lectures and/or travel reimbursements not related to this study from Pfizer, United Medical, and Gilead Sciences. Other authors declare no conflict of interest.Funding StatementWe did not have any funding support for this study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe hereby choose to not share our dataset.